Ohshima S, Kinukawa T, Matsuura O, Takeuchi N, Hattori R, Hashimoto J, Ono Y, Watanabe J, Yamada S, Kamihira O
Department of Urology, Shakai Hoken Chykyo Hospital.
Nihon Hinyokika Gakkai Zasshi. 1990 Feb;81(2):225-9. doi: 10.5980/jpnjurol1989.81.225.
The results of 20 HLA 1-haploidentical donor kidney transplant patients treated with preoperative lymphocyte deletion through thoracic duct drainage and low dose of cyclosporine and steroid immunosuppressive therapy, were presented. The number of removed lymphocytes was 114 +/- 36 X 10(9) (mean +/- SD) and the duration of thoracic duct drainage was 35 +/- 7 days. Graft survival was 100% at 3-9 months and 89% at 1-2 years after transplantation. Patient survival was 100% at 3-9 months and 89% at 1-2 years. A patient died from lung cancer (adenocarcinoma) in the 9th posttransplant month. Acute rejection was not seen in 20 patients during the first 3 months. Life-threatening infectious disease was never seen either. Diabetes mellitus was observed in 1 patient. No other complications were observed. These results indicated that thoracic duct drainage and low dose cyclosporine and steroid postoperative immunosuppressive treatment might yield complete success in HLA 1-haploidentical kidney transplant patients.
报告了20例接受术前经胸导管引流淋巴细胞清除术并联合低剂量环孢素和类固醇免疫抑制治疗的HLA 1半相合供体肾移植患者的结果。清除的淋巴细胞数量为114±36×10⁹（平均值±标准差），胸导管引流持续时间为35±7天。移植后3至9个月时移植物存活率为100%，1至2年时为89%。患者存活率在3至9个月时为100%，1至2年时为89%。一名患者在移植后第9个月死于肺癌（腺癌）。20例患者在最初3个月内未出现急性排斥反应。也从未见过危及生命的传染病。观察到1例患者患有糖尿病。未观察到其他并发症。这些结果表明，胸导管引流以及术后低剂量环孢素和类固醇免疫抑制治疗可能在HLA 1半相合肾移植患者中取得完全成功。
